Background The efficacy and effectiveness of the quadrivalent human papillomavirus (HPV)
vaccine in preventing high-grade cervical lesions have been shown. However, data to …

Background In clinical trials, vaccines against human papillomavirus (HPV) have been
highly effective against HPV16-or HPV18-associated cervical lesions. The quadrivalent HPV …

Background Human papillomavirus (HPV) immunisation with a bivalent vaccine (Cervarix)
was introduced in England, UK, in Sept 1, 2008: routine vaccination was offered to girls …

Human papillomavirus (HPV) types 16/18, included in HPV vaccines, contribute to the
majority of cervical cancer, and a substantial proportion of cervical intraepithelial neoplasia …

Aim Prophylactic human papillomavirus (HPV) vaccines are highly effective at preventing
pre–cancerous cervical lesions when given in a three–dose schedule. Some post–hoc trial …

Background The primary goal of human papillomavirus (HPV) vaccination is to reduce
morbidity and mortality from HPV-associated disease, especially cervical cancer. We …

Background Human papillomavirus (HPV) vaccination protects against HPV, a necessary
risk factor for cervical cancer. We now report results from population-based follow-up of …

Background Incidence of condyloma, or genital warts (GW), is the earliest possible disease
outcome to measure when assessing the effectiveness of human papillomavirus (HPV) …

Background Candidate human papillomavirus (HPV) vaccines have demonstrated almost
90%-100% efficacy in preventing persistent, type-specific HPV infection over 18 mo in …

Background High-risk human papillomavirus causes cervical cancer. Vaccines have been
developed that significantly reduce the incidence of preinvasive and invasive disease. This …